Preoperative atorvastatin reduces bleeding and blood transfusions in patients undergoing elective isolated aortic valve replacement.
Aged
Anticholesteremic Agents
/ therapeutic use
Aortic Valve
/ surgery
Atorvastatin
/ therapeutic use
Blood Transfusion
/ statistics & numerical data
Cardiac Surgical Procedures
/ adverse effects
Elective Surgical Procedures
/ adverse effects
Female
Heart Valve Diseases
/ surgery
Heart Valve Prosthesis
Humans
Incidence
Italy
/ epidemiology
Male
Postoperative Hemorrhage
/ epidemiology
Preoperative Care
/ methods
Retrospective Studies
Aortic valve replacement
Bleeding
Cardiopulmonary bypass
Length of stay
Statin
Transfusion
Journal
Interactive cardiovascular and thoracic surgery
ISSN: 1569-9285
Titre abrégé: Interact Cardiovasc Thorac Surg
Pays: England
ID NLM: 101158399
Informations de publication
Date de publication:
01 07 2019
01 07 2019
Historique:
received:
14
08
2018
revised:
28
11
2018
accepted:
11
12
2018
pubmed:
13
2
2019
medline:
18
12
2019
entrez:
13
2
2019
Statut:
ppublish
Résumé
Minimization of bleeding to reduce the use of blood products is of utmost importance in cardiac surgery. Statins are known for their pleiotropic effects beyond lipid-lowering properties, and the use of atorvastatin preoperatively is associated with reduced risk of bleeding and blood product use after coronary surgery. However, no studies have investigated if this beneficial effect also extends to aortic valve surgery. In this retrospective cohort study, 1145 consecutive patients undergoing elective primary isolated aortic valve replacement meeting the inclusion and exclusion criteria were selected from January 2009 to December 2017 (547 in the atorvastatin group, 598 in the control group). Postoperative bleeding, blood product use, and complications were monitored during hospitalization. Postoperative bleeding was significantly lower in the atorvastatin group compared with the controls in the first 12 h after surgery (372 ± 137 vs 561 ± 219 ml; P = 0.001) and considering overall bleeding (678 ± 387 vs 981 ± 345 ml, P = 0.001). A total of 32.3% of controls and 26.3% of atorvastatin users received packed red blood cells (P = 0.027), and major surgical complications were similar between the groups. Postoperative length of stay was shorter in the atorvastatin group with an average reduction of 1 day of hospitalization (6.0 ± 1.4 vs 6.9 ± 2.1 days; P = 0.001). Postoperative bleeding among the atorvastatin-treated patients was significantly greater in those taking lower doses compared to those taking higher doses of atorvastatin with a 20% between-group difference (P = 0.001). Preoperative treatment with atorvastatin might reduce postoperative bleeding and transfusion of packed red blood cells in patients undergoing elective isolated aortic valve replacement. This result might translate into faster recovery after surgery and reduced hospitalization costs.
Identifiants
pubmed: 30753487
pii: 5316004
doi: 10.1093/icvts/ivz012
doi:
Substances chimiques
Anticholesteremic Agents
0
Atorvastatin
A0JWA85V8F
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
51-58Informations de copyright
© The Author(s) 2019. Published by Oxford University Press on behalf of the European Association for Cardio-Thoracic Surgery. All rights reserved.